Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events

Immune checkpoint inhibitors (ICIs) are able to reactivate the immune system, thereby enhancing the anti‐tumor effects. However, over‐activated T cells may induce immune‐related adverse events (irAEs). Hematological irAEs are rarely reported which mainly represent monolineage cytopenia or pancytopen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thorac Cancer
Hlavní autoři: Zhuang, Junling, Du, Jianhua, Guo, Xiaoxiao, Zhou, Jiaxin, Duan, Lian, Qiu, Wei, Si, Xiaoyan, Zhang, Li, Li, Yue, Liu, Xiaowei, Wang, Hanping, Zhou, Daobin
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons Australia, Ltd 2020
Témata:
Clinical Guideline
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049514/
https://ncbi.nlm.nih.gov/pubmed/32017466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13281
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky